Tag: precision oncology
AstraZeneca Licenses Novel Lung Cancer Drug Zegfrovy in $1.5B Global Deal
AstraZeneca announced a exclusive global license agreement with Dizal Pharmaceutical to develop and commercialize Zegfrovy (sunvozertinib), a highly differentiated, oral irreversible EGFR inhibitor designed for targeted lung cancer...
GSK Launches Tender Offer to Acquire Precision Oncology Innovator Nuvalent, Inc.at $124.00
GSK plc has officially commenced a tender offer to acquire all issued and outstanding shares of Class A and Class B common stock of Nuvalent,...
Novartis strikes a $1.9B partnership with Antares Therapeutics to tackle “undruggable” cancer targets.
Novartis has entered into a strategic collaboration and license agreement with Antares Therapeutics to discover and develop next-generation small molecule oncology treatments. The transaction...
Johnson & Johnson to acquire Firefly Bio to advance novel cancer treatment
Johnson & Johnson announced that it has entered into a definitive agreement to acquire Firefly Bio, Inc., a privately held biotechnology company specializing in...